Literature DB >> 17532833

Renal replacement therapies in pediatric intensive care patients: experiences of one center in Turkey.

Tanil Kendirli1, Mesiiha Ekim, Zeynep Birsin Ozçakar, Selçuk Yüksel, Banu Acar, Burcu Oztürk-Hiişmi, Emel Derelli, Asli Kavaz, Zahide Yalaki, Fatoş Yalçinkaya.   

Abstract

BACKGROUND: Despite constant improvements in caring for critically ill neonates and infants with congenital cardiac disease, sepsis, bone marrow and solid organ transplantation, acute renal failure (ARF) is an important problem in these children. ARF, severe fluid overload and inborn errors of metabolism are some of the indications for acute dialysis in infants and children.
METHODS: The authors had retrospectively evaluated the medical records of Pediatric Intensive Care Unit, Ankara University School of Medicine, Ankara, Turkey patients who had required acute renal replacement therapy between the dates of January 2002 to February 2005.
RESULTS: Medical records of 332 patients were reviewed. Acute renal replacement therapy was performed in 21 patients (6.3%; mean age, 9.6 +/- 7.4 years). Dialysis modalities were peritoneal dialysis in 15 patients (71.4%; mean age, 3.9 +/- 5.6 years) and hemodialysis in six patients (28.6%; mean age, 12.1 +/- 3.2 years). A total of 90% of patients had severe systemic disease leading to ARF. A total of 95% of patients had multiple organ dysfunction syndrome. The most common cause of ARF was refractory shock. At the beginning of renal replacement therapy, 10 patients were anuric, nine patients had volume overload, seven patients had decompensated metabolic acidosis and nine patients had hypotension. The average dialysis period was 4.7 +/- 6.4 days. Mortality rate was 66.7%. Eight patients recovered from ARF and chronic renal failure had developed in one patient.
CONCLUSION: In the Pediatric Intensive Care Unit, ARF is frequently seen together with multiple organ dysfunction syndrome and the mortality rate is high. Both peritoneal dialysis and hemodialysis are important renal replacement treatment modalities in patients with ARF. The age and hemodynamic status of the patients are important when choosing treatment modality; generally peritoneal dialysis is preferred in infants and toddler, while hemodialysis is preferred in older children.

Entities:  

Mesh:

Year:  2007        PMID: 17532833     DOI: 10.1111/j.1442-200X.2007.02376.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  5 in total

Review 1.  Peritoneal dialysis for the management of pediatric patients with acute kidney injury.

Authors:  Anil Vasudevan; Kishore Phadke; Hui-Kim Yap
Journal:  Pediatr Nephrol       Date:  2016-10-28       Impact factor: 3.714

2.  Assessment of Worldwide Acute Kidney Injury, Renal Angina and Epidemiology in Critically Ill Children (AWARE): A Prospective Study to Improve Diagnostic Precision.

Authors:  Rajit K Basu; Ahmad Kaddourah; Tara Terrell; Theresa Mottes; Patricia Arnold; Judd Jacobs; Jennifer Andringa; Melissa Armor; Lauren Hayden; Stuart L Goldstein
Journal:  J Clin Trials       Date:  2015-04-17

3.  Acute kidney injury: A pediatric experience over 10 years at a tertiary care center.

Authors:  Alaleh Gheissari; Pardis Mehrasa; Alireza Merrikhi; Yahya Madihi
Journal:  J Nephropathol       Date:  2012-07-01

4.  Assessment of Worldwide Acute Kidney Injury, Renal Angina and Epidemiology in critically ill children (AWARE): study protocol for a prospective observational study.

Authors:  Rajit K Basu; Ahmad Kaddourah; Tara Terrell; Theresa Mottes; Patricia Arnold; Judd Jacobs; Jennifer Andringa; Stuart L Goldstein
Journal:  BMC Nephrol       Date:  2015-02-26       Impact factor: 2.388

Review 5.  Acute Kidney Injury Recognition and Management: A Review of the Literature and Current Evidence.

Authors:  Syed Raza Shah; Sameer Altaf Tunio; Mohammad Hussham Arshad; Zorays Moazzam; Komal Noorani; Anushe Mohsin Feroze; Maham Shafquat; Huma Syed Hussain; Syed Ali Hyder Jeoffrey
Journal:  Glob J Health Sci       Date:  2015-09-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.